author-photo

Yauheni Valerievich Baranau

5

Papers

76

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer

2018 Expert Review of Anticancer Therapy
Show All
- Source
- Cite
- Save
Citations (3)
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (58)
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
152PDDouble-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
The experience of administration of high-dose recombinant interleukin-2 in combination with chemotherapy in the management of disseminated skin melanoma.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)